tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

CGON Stock Latest News

J&J data presents ‘limited downside’ to CG Oncology, says Goldman Sachs
The FlyJ&J data presents ‘limited downside’ to CG Oncology, says Goldman Sachs
3d ago
JNJ
CGON
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
PremiumPress Releases
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
20d ago
CGON
CG Oncology initiated with a Buy at Roth MKM
PremiumThe Fly
CG Oncology initiated with a Buy at Roth MKM
23d ago
CGON
CG Oncology reports Q2 EPS (28c), consensus (37c)
PremiumThe Fly
CG Oncology reports Q2 EPS (28c), consensus (37c)
1M ago
CGON
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
PremiumPress Releases
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
1M ago
CGON
CG Oncology 4.068M share Block Trade priced at $33.90
PremiumThe FlyCG Oncology 4.068M share Block Trade priced at $33.90
2M ago
CGON
CG Oncology initiated with Buy on bladder cancer potential at BofA
Premium
The Fly
CG Oncology initiated with Buy on bladder cancer potential at BofA
3M ago
CGON
CG Oncology initiated with a Buy at BofA
Premium
The Fly
CG Oncology initiated with a Buy at BofA
3M ago
CGON
CG Oncology initiates EAP for Cretostimogene Grenadenorepvec in U.S.
PremiumThe Fly
CG Oncology initiates EAP for Cretostimogene Grenadenorepvec in U.S.
3M ago
CGON
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
PremiumPress Releases
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
3M ago
CGON
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
PremiumPress Releases
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
4M ago
CGON
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
PremiumPress Releases
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
4M ago
CGON
CG Oncology upgraded to Buy from Neutral at Goldman Sachs
PremiumThe FlyCG Oncology upgraded to Buy from Neutral at Goldman Sachs
4M ago
CGON
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Premium
Press Releases
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
4M ago
CGON
CG Oncology expects cash runway through 2027
Premium
The Fly
CG Oncology expects cash runway through 2027
4M ago
CGON
CG Oncology reports Q1 EPS (36c) vs. ($3.22) last year
PremiumThe Fly
CG Oncology reports Q1 EPS (36c) vs. ($3.22) last year
4M ago
CGON
3 Best Stocks to Buy Now, 5/9/2024, According to Top Analysts 
PremiumMarket News
3 Best Stocks to Buy Now, 5/9/2024, According to Top Analysts 
4M ago
ALAB
CGON
3 Best Stocks to Buy Now, 5/7/2024, According to Top Analysts 
PremiumMarket News
3 Best Stocks to Buy Now, 5/7/2024, According to Top Analysts 
5M ago
CGON
GENI
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
5M ago
JNJ
CGON
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
PremiumThe FlyCantor Fitzgerald biotech analysts hold an analyst/industry conference call
5M ago
JNJ
CGON
3 Best Stocks to Buy Now, 5/6/2024, According to Top Analysts 
Premium
Market News
3 Best Stocks to Buy Now, 5/6/2024, According to Top Analysts 
5M ago
CGON
ELEV
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Premium
Press Releases
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
5M ago
CGON

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >